In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors

Infection and Immunity

Volumn 68, Issue 1, 2000, Pages 205-213

  Plckett, Thames E ^a,b   Pasetti, Marcela F ^a   Galen, James E ^a   Sztein, Marcelo B ^a,b   Levine, Myron M ^a,b,c  

^a Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; TETANUS ANTIBODY; TYPHOID VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; TYPHOID FEVER; VACCINATION;

EID: 0033981934     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.68.1.205-213.2000     Document Type: Article

References (26)

1. Barry, E. M., O. G. Gomez-Duarte, S. Chatfield, R. Rappuoli, M. Pizza, G. Losonsky, J. E. Galen, and M. M. Levine. 1996. Expression and immunogenicity of pertussis S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect. Immun. 64:4172-4181.
2. Carter, P. B., and F. M. Collins. 1974. Growth of typhoid and paratyphoid bacilli in intravenously infected mice. Infect. Immun. 10:816-822.
3. Carter, P. B., and F. M. Collins. 1974. The route of infection in normal mice. J. Exp. Med. 139:1189-1203.
4. Chatfield. S. N., I. G. Charles, A. J. Makoff. M. D. Oxer, G. Dougan, D. Pickard, D. Slater, and N. F. Fairweather. 1992. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Bio/ Technology 10:888-892.
5. Everest, P., G. Frankel, J. Li, P. Lund, S. Chatfield, and G. Dougan. 1995. Expression of LacZ from htrA. nirB, and groE. promoters in a Salmonella vaccine strain: influence of growth in mammalian cells. FEMS Microbiol. Lett. 126:97-101.
6. Fairweather, N. F., S. N. Chatfield, A. J. Makoff, R. A. Strugnell, J. Bester, D. J. Maskell, and G. Dougan. 1990. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier. Infect. Immun. 58:1323-1326.
7. Franke-Ullmann, G., C. Pfortner, P. Walter, C. Steinmuller, M. Lohmann-Matthes, and L. Kobzik. 1996. Characterization of murine lung interstitial macrophages in comparison with alveolar macrophages in vitro. J. Immunol. 157:3097-3104.
8. Galen, J. E., O. G. Gomez-Duarte, G. A. Losonsky, J. L. Halpern, C. S. Lauderbaugh, S. Kaintuck, M. K. Reymann, and M. M. Levine. 1997. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to foreign antigens. Vaccine 15:700-708.
9. Gonzalez, C., D. Hone, F. R. Noriega, C. O. Tacket, J. R. Davis, G. A. Losonsky, J. P. Nataro, S. Hoffman. A. Malik, E. Nardin, M. B. Sztein, D. G. Heppner, T. R. Fouts, A. Isibasi, and M. M. Levine. 1994. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity. J. Infect. Dis. 169:927-931.
10. Gross, E. A., J. A. Swenberg, S. Fields, and J. A. Popp. 1982. Comparative morphometry of the nasal cavity in rats and mice. J. Anat. 135:83-88.
11. Heritage, P. L., B. J. Underdown, A. L. Arsenault, D. P. Snider, and M. R. McDermott. 1997. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am. J. Respir. Crit. Care Med. 156:1256-1262.
12. Hohmann, E. L., C. A. Oletta, K. P. Killeen, and S. I. Miller. 1996. phoP/ phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic singledose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1408-1414.
13. Hoiseth, S., and B. A. D. Stocker. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and are effective as live vaccines. Nature 291: 238-239.
14. Hone, D. M., S. R. Attridge, B. Forrest, R. Morona, D. Daniels, J. T. LaBrooy, R. C. Bartholomeusz, D. J. C. Shearman, and J. Hackett. 1988. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect. Immun. 56:1326-1333.
15. Hone, D. M., C. O. Tacket, A. M. Harris, B. Kay, G. A. Losonsky, and M. M. Levine. 1992. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J. Clin. Investig. 90:412-420.
16. Masui, Y., T. Mizuno, and M. lnouye. 1984. Novel high-level expression cloning vehicles: 10,000-fold amplification of Escherichia coli minor protein. Bio/Technology 2:81-85.
17. O'Brien, A. D. 1982. Innate resistance of mice to Salmonella typhi infection. Infect. Immun. 38:948-952.
18. 197, and its fragment in Salmonella typhi vaccine strain CVD 908-htrA. Infect. Immun. 67:4290-4294.
19. Pasetti, M. F., R. J. Anderson, F. R. Noriega, M. M. Levine, and M. B. Sztein. 1999. Attenuated ΔguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin. Immunol. 92:76-89.
20. Oxer, M. D., C. M. Bentley, J. G. Doyle, T. C. Peakman, I. G. Charles, and A. J. Makoff. 1991. High level heterologous expression in E. coli using the anaerobically-activated nirB promoter. Nucleic Acids Res. 19:2889-2892.
21. Sztein, M. B., M. K. Tanner, Y. Polotsky. J. M. Orenstein, and M. M. Levine. 1995. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J. Immunol. 155:3987-3993.
22. Sztein, M. B., S. A. Wasserman, C. O. Tacket, R. Edelman, D. Hone. A. A. Lindberg, and M. M. Levine. 1994. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 170:1508-1517.
23. Tacket, C. O., D. M. Hone, G. A. Losonsky, L. Guers, R. Edelman, and M. M. Levine. 1992. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 10:443-446.
24. Tacket, C. O., M. B. Sztein, G. A. Losonsky, S. A. Wasserman, J. P. Nataro, R. Edelman, D. Pickard, S. Chatfield, and M. M. Levine. 1997. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65:452-456.
25. Vladoianu, I., H. R. Chang, and J. Pechere. 1990. Expression of host resistance to Salmonella typhi and Salmonella typhimurium: bacterial survival within macrophages of murine and human origin. Microb. Pathog. 8:83-90.
26. Wu, H.-Y., H. H. Nguyen, and M. W. Russell. 1907. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand. J. Immunol. 46:506-517.